The development of therapy resistance means that cancer therapies are no longer effective over time. In many cases, this leads to a recurrence of the tumour. The consequences for the success of the patient's treatment are usually fatal and place a high cost burden on the healthcare system. Understanding how resistance develops and which strategies can be used to resensitise treatment is a key challenge for modern cancer research.

As part of P-CARE, a joint platform is being established to identify those drugs that can re-sensitise resistant tumours to therapies. This can be achieved, among other things, by so-called repositioning of drugs, i.e. a new application of active substances that are already authorised for the treatment of other diseases. In terms of personalised medicine, the immune response of the tumour microenvironment is reproduced in vitro and used to research how immunotherapy resistance can be overcome.

P-CARE will create a cross-border network in the academic and clinical cancer research sector for the joint use of technologies and expertise, which will also be accessible outside the programme area.

P-Care is funded by the European Union, the EFRD (European Regional Development Fund) and the Interreg V-A Italy-Austria 2014-2020 programme.

‍